Literature DB >> 19597524

Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213.

Yu-si Cheng1, De-zai Dai, Yin Dai.   

Abstract

AIM: Spatial dispersion of bioactive substances in the myocardium could serve as pathological basis for arrhythmogenesis and cardiac impairment by beta-adrenoceptor stimulation. We hypothesized that dispersed NADPH oxidase, protein kinase Cepsilon (PKCepsilon), early response gene (ERG), and matrix metalloproteinase 9(MMP-9) across the heart by isoproterenol (ISO) medication might be mediated by the endothelin (ET) - ROS pathway. We aimed to verify if ISO induced spatially heterogeneous distribution of pPKCepsilon, NAPDH oxidase, MMP-9 and ERG could be mitigated by either an ET receptor antagonist CPU0213 or iNOS inhibitor aminoguanidine.
METHODS: Rats were treated with ISO (1 mg/kg sc) for 10 days, and drug interventions (mg/kg) either CPU0213 (30 sc) or aminoguanidine (100 ip) were administered on days 8-10. Expression of NADPH oxidase, MMP-9, ERG, and PKCepsilon in the left and right ventricle (LV, RV) and septum (S) were measured separately.
RESULTS: Ventricular hypertrophy was found in the LV, S, and RV, in association with dispersed QTc and oxidative stress in ISO-treated rats. mRNA and protein expression of MMP-9, PKCepsilon, NADPH oxidase and ERG in the LV, S, and RV were obviously dispersed, with augmented expression mainly in the LV and S. Dispersed parameters were re-harmonized by either CPU0213, or aminoguanidine.
CONCLUSION: We found at the first time that ISO-induced dispersed distribution of pPKCepsilon, NADPH oxidase, MMP-9, and ERG in the LV, S, and RV of the heart, which were suppressed by either CPU0213 or aminoguanidine. It indicates that the ET-ROS pathway plays a role in the dispersed distribution of bioactive substances following sustained beta-receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597524      PMCID: PMC4006683          DOI: 10.1038/aps.2009.104

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  40 in total

1.  The antiarrhythmic effect of centrally administered rilmenidine involves muscarinic receptors, protein kinase C and mitochondrial signalling pathways.

Authors:  M Iwasaki; Y Hayashi; T Kamibayashi; A Yamatodani; T Mashimo
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

2.  Effects of angiotensin-converting enzyme inhibitor therapy on QT dispersion post acute myocardial infarction.

Authors:  John Kassotis; Mbu Mongwa; C V R Reddy
Journal:  Pacing Clin Electrophysiol       Date:  2003-04       Impact factor: 1.976

3.  Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy.

Authors:  Indira K Adiga; Renuka R Nair
Journal:  Cell Biochem Funct       Date:  2008-04       Impact factor: 3.685

4.  Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin.

Authors:  Yu-Si Cheng; De-Zai Dai; Yin Dai
Journal:  J Pharm Pharmacol       Date:  2009-05       Impact factor: 3.765

5.  Hypoxia suppresses the production of MMP-9 by human monocyte-derived dendritic cells and requires activation of adenosine receptor A2b via cAMP/PKA signaling pathway.

Authors:  Peng Zhao; Xin-gang Li; Meixiang Yang; Qianqian Shao; Donghai Wang; Shuxun Liu; Haibo Song; Bingfeng Song; Yan Zhang; Xun Qu
Journal:  Mol Immunol       Date:  2008-01-22       Impact factor: 4.407

6.  Meta-analysis of effect of statin treatment on risk of sudden death.

Authors:  Giacomo Levantesi; Marco Scarano; RosaMaria Marfisi; Giovanna Borrelli; Anne W S Rutjes; Maria Giuseppina Silletta; Gianni Tognoni; Roberto Marchioli
Journal:  Am J Cardiol       Date:  2007-10-24       Impact factor: 2.778

7.  Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure.

Authors:  K S Moshal; W E Rodriguez; U Sen; S C Tyagi
Journal:  Physiol Res       Date:  2007-05-30       Impact factor: 1.881

8.  Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications.

Authors:  Jane Chiu; Bing Ying Xu; Shali Chen; Biao Feng; Subrata Chakrabarti
Journal:  Can J Physiol Pharmacol       Date:  2008-06       Impact factor: 2.273

Review 9.  Evidence for the regulation of L-type Ca2+ channels in the heart by reactive oxygen species: mechanism for mediating pathology.

Authors:  Livia C Hool
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-02       Impact factor: 2.557

10.  Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent.

Authors:  Rong-Hui Du; Hong-Wei Yi; De-Zai Dai; Wei-Hua Tang; Yin Dai
Journal:  J Pharm Pharmacol       Date:  2008-08       Impact factor: 3.765

View more
  4 in total

Review 1.  The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases.

Authors:  A Rietz; Jp Spiers
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in rats.

Authors:  Yu-si Cheng; De-zai Dai; Hui Ji; Qi Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2011-03-28       Impact factor: 6.150

3.  CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity.

Authors:  Min-you Qi; Yu Feng; De-zai Dai; Na Li; Yu-si Cheng; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

4.  Vascular endothelial cells mediate mechanical stimulation-induced enhancement of endothelin hyperalgesia via activation of P2X2/3 receptors on nociceptors.

Authors:  Elizabeth K Joseph; Paul G Green; Oliver Bogen; Pedro Alvarez; Jon D Levine
Journal:  J Neurosci       Date:  2013-02-13       Impact factor: 6.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.